Trending/Edith Perez
Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2+ Breast Cancer Patients, Study Finds
JACKSONVILLE, Fla. — A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also…
Special Topics
Sign up

Mayo Clinic Connect
An online patient support community